As of 2024-12-14, the Relative Valuation of Harvard Bioscience Inc (HBIO) is (10.78) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.24 USD, the upside of Harvard Bioscience Inc based on Relative Valuation is -581.3%.
The range of the Relative Valuation is (10.21) - (11.06) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 31.3x - 34.9x | 33.3x |
| Forward P/E multiples | 30.9x - 33.9x | 32.8x |
| Fair Price | (10.21) - (11.06) | (10.78) |
| Upside | -555.6% - -593.8% | -581.3% |
| Date | P/E |
| 2024-12-12 | -6.89 |
| 2024-12-11 | -7.11 |
| 2024-12-10 | -7.17 |
| 2024-12-09 | -7.14 |
| 2024-12-06 | -6.92 |
| 2024-12-05 | -6.55 |
| 2024-12-04 | -6.92 |
| 2024-12-03 | -6.86 |
| 2024-12-02 | -6.74 |
| 2024-11-29 | -6.74 |
| 2024-11-27 | -6.74 |
| 2024-11-26 | -6.71 |
| 2024-11-25 | -6.86 |
| 2024-11-22 | -6.95 |
| 2024-11-21 | -6.62 |
| 2024-11-20 | -6.62 |
| 2024-11-19 | -6.28 |
| 2024-11-18 | -6.59 |
| 2024-11-15 | -6.55 |
| 2024-11-14 | -7.01 |
| 2024-11-13 | -6.65 |
| 2024-11-12 | -6.98 |
| 2024-11-11 | -7.50 |
| 2024-11-08 | -7.87 |
| 2024-11-07 | -7.32 |
| 2024-11-06 | -8.64 |
| 2024-11-05 | -7.32 |
| 2024-11-04 | -7.26 |
| 2024-11-01 | -7.35 |
| 2024-10-31 | -7.20 |
| 2024-10-30 | -7.50 |
| 2024-10-29 | -7.50 |
| 2024-10-28 | -7.41 |
| 2024-10-25 | -7.11 |
| 2024-10-24 | -7.17 |
| 2024-10-23 | -7.23 |
| 2024-10-22 | -7.35 |
| 2024-10-21 | -7.26 |
| 2024-10-18 | -7.57 |
| 2024-10-17 | -7.32 |
| 2024-10-16 | -7.47 |
| 2024-10-15 | -7.50 |
| 2024-10-14 | -7.63 |
| 2024-10-11 | -7.75 |
| 2024-10-10 | -7.11 |
| 2024-10-09 | -7.26 |
| 2024-10-08 | -7.35 |
| 2024-10-07 | -7.35 |
| 2024-10-04 | -7.35 |
| 2024-10-03 | -7.53 |